Pharmaceutical
Indications

 

39 Results were found on Technologies

Leading Researchers:
10-2013-551

Novel Integrase Based Cancer Treatment Technology

We have developed a new gene therapy technology for specific cancer cells killing and validated both efficacy and safety superiority of the proposed system over the conventional one in lung cancer mice model. The proposed system offers advantages... Read More >

Leading Researchers:
10-2019-1237

A Promising New Target Epitope for the Treatment of Neurodegenerative Diseases

• GSK‐3, is a promising drug target for treating multiple pathological disorders like Alzheimer’s diseases, Fragile X and Huntington’s disease. • Most GSK‐3 inhibitors that were developed function as... Read More >

Leading Researchers:
2-2020-1451

Leveraging Gene Panel Sequencing Data for Mutational Signature Analysis with Applications to Personalized Treatment

UNMET NEEDMutational signatures and their exposures are key to understanding the processes that shape cancer genomes with applications to diagnosis and treatment. Yet current signature analysis approaches are limited to relatively rich mutation... Read More >

Leading Researchers:
10-2007-109

Macrolid Induced Correction of Premature Stop Codons: A novel Treatment for Colorectal Cancer

Restoration of premature termination codons (PTCs) caused by nonsense mutations for the treatment of Familial Adenomatous Polyposis. The Need Familial Adenomatous Polyposis (FAP) is a high penetrance devastating syndrome manifested by... Read More >

Leading Researchers:
2-2020-1440

Novel Anti-Tumor Response treatment targeting ErbB receptors and Nucleolin interactions

ErbBs subfamily receptors are mediators of cell growth signals. They have long been associated with a wide variety of lung, ovarian, colon, breast, prostate, and other carcinomas. Nucleolin is a major nucleolar protein of growing eukaryotic cells... Read More >

10-2013-549

Novel specific disease-modifying PERK activator for Huntington’s disease

There is no efficient therapy at present for Huntington’s disease (HD) nor for any other neurodegenerative disease, including Alzheimer’s and Parkinson’s diseases. No disease-modifying approaches exist. Gene therapy-based clinical trials have... Read More >

Leading Researchers:
2-2020-1376

New Chemiluminescent Protease Probe for Rapid, Sensitive, and Inexpensive Detection of Live Mycobacterium tuberculosis

Tuberculosis (TB) is a top-ten cause of death worldwide. Successful treatment is often limited by insufficient diagnostic capabilities, especially at the point of care in low-resource settings. The ideal diagnostic must be fast, be cheap, and... Read More >

Leading Researchers:
2-2021-1566

Therapeutic Targeting of PD-1/PD-L1 blockade by Novel Small-molecule Inhibitors

Interactions between programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) lead to the evasion of cancer cells from an efficient immune response. The inhibition of PD-L1/PD-1 has prevented or reversed exhausted T cells,... Read More >

Leading Researchers:
10-2012-314

Repurposing of Antibiotics for treating APC (Adenomatous Polyposis Coli) Related Colorectal Cancer

Restoration of Adenomatous Polyposis Coli (APC) gene expression by means of antibiotic erythromycin for the treatment of Familial Adenomatous Polyposis. The Technology:Treatment for APC by conventional antibiotics to regulate adenoma... Read More >

Leading Researchers:
10-2020-1360

Targeting Human Brain Cells With Adeno-Associated Virus (AAV) for a Prospective Therapeutic Approach

The AAV therapeutic approach for various central nervous system (CNS) illnesses has been rapidly growing. Unfortunately, existing present technologies utilize AAV administration that is injected locally into the brain. This process requires a high... Read More >